Hikma Pharmaceuticals PLC said on Thursday it has completed its acquisition of the Canadian assets of Teligent Inc.

The London-based pharmaceutical company said the acquisition marks the company’s expansion into Canada and includes a portfolio of 25 sterile injectable productions, three in-licenced eye-related products and seven additional products in the pipeline.

The acquisition was originally announced on January 17 for a price of $45.8 million. Teligent is a pharmaceutical company based in New Jersey, US that focuses on topical and injectable medicines.

President of Hikma Injectables Riad Mishlawi said: ‘The completion of this acquisition expands Hikma’s presence in the highly attractive Canadian injectables market, bringing a strong portfolio of sterile injectable products, as well as strengthening our pipeline. We are excited to bring these important products to our Canadian customers and their patients.’

Shares in Hikma were down 0.8% at 2,027.00 pence on Thursday morning in London.

Copyright 2022 Alliance News Limited. All Rights Reserved.